SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
RLYB

Rallybio Corp (NASDAQ:RLYB)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$15.47-$0.05 (-0.32%)
 
Market cap
$83.3M
Insider Score
Health Score
Analyst consensus
Listed since
Jul 29, 2021
Market Cap$83.29M+204.5%
Revenue (ttm)$434.00K-35.6%
Net Income$26.81M+289.2%
EPS$4.48+272.3%
Shares Out5.38M
PE Ratio3.36
Forward PEn/a
Dividend$13.56(87.65%)
Ex-Dividend DateNov 23, 2026
Volume50,485
Open$15.20
Previous Close$15.52
Day's Range$15.20 - $15.62
52-Week Range$3.67 - $35.15
Betan/a
AnalystsHold
Price Targetn/a
Earnings DateMar 11, 2027
-0.97% (1D)
No price history available.

About RLYB

Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company's pipeline also includes RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for addressing ophthalmic conditions driven by complement system activity. Furthermore, RLYB116, an inhibitor designed to target complement component 5 (C5) for various complement dysregulation disorders, has successfully completed its Phase 1 trial. Another preclinical antibody, RLYB332, is under investigation for treating severe anemia characterized by ineffective erythropoiesis and iron overload. Rallybio has established strategic collaborations to further its development efforts. It maintains an alliance with AbCellera for the identification, development, and commercialization of novel antibody-based therapeutics in rare diseases. Additionally, the firm partners with Exscientia on the creation of small molecule therapeutics for rare diseases, and with Johnson & Johnson to deliver therapeutic options to expectant mothers at risk of fetal and neonatal alloimmune thrombocytopenia. Established in 2018, Rallybio Corporation is headquartered in New Haven, Connecticut.

Address
234 Church Street, New Haven, CT, 06510, US
Market Cap
83 million
Employees
6
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$9.61K
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Strong
From RLYB’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-0.32%
5 Days
-2.34%
1 Month
-5.67%
6 Months
-2.58%
1 Year
+204.53%

$RLYB stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in RLYB holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by RLYB's directors and management

Net Shares Purchased by Insiders−600−30002025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

RLYB Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New RLYB patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to RLYB from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in RLYB

VTIVanguard Morningstar Total Stock Market ETF$1.65M
VXFVanguard Extended Market ETF$574.06K
IWCiShares Micro-Cap ETF$176.64K
AVSCAvantis U.S. Small Cap Equity ETF$24.24K
DFASDimensional - US Small Cap ETF$1.80K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from RLYB’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
71% of score
0
Analyst Ratings
No data yet
—
News & Sentiment
29% of score
60

News check: Merger closing with concurrent $215M financing represents positive capital event and business development; reverse split is neutral administrative action typical in merger transactions.

Recent Insider Activity

Buys
0
Sells
1
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.